Norwegian krill harvester and processor Aker BioMarine has appointed Katina Handeland and Yunpeng Ding as directors for Research & Development (R&D).
The pair will be responsible for research within the company’s human health and nutrition department.
Handeland, who has extensive experience in innovation projects for medical nutrition, will be working to both design and follow up the pre-clinical and clinical human health trials, studying the biological effects of krill and its benefits.
Ding previously worked with drug development and early-phase clinical trials, and has most recently served as a senior statistician for a medical research company in Norway.
His focus will be on krill oil and its potential for sports performance, metabolic syndrome, as well as cardiovascular and cognitive health.
Last week Aker BioMarine, which trades on the Oslo Stock Exchange, posted $19.4 million (€16.5 million) in adjusted second quarter earnings before interest, taxes, depreciation and amortization (EBITDA), up 10 percent from the same period last year. Revenues during the period reached $74.3 million (€63.1 million).
The group said its results were impacted by poor krill harvesting conditions, with fishing volumes declining to 13,920 metric tons from 16,387 metric tons during the second quarter of last year.